PROGRAM |
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
|
PARTNER | TERRITORY |
---|---|---|---|
Type 1 Diabetes
|
JDRF
|
|
|
CFRD
Type 2 Diabetes
|
Cystic Fibrosis Foundation
Huadong Medicine
|
China and Pac Rim (excl. Japan)
|
|
SAD/MAD Completed
Psoriasis
COPD
Atopic Dermatitis
|
|
China and Pac Rim (excl. Japan)
China and Pac Rim (excl. Japan)
China and Pac Rim (excl. Japan)
|
|
HPP593
PPAR-δ activator |
Primary Mitochondrial Myopathy
|
|
Worldwide
|
Azeliragon
RAGE antagonist |
Pancreatic Cancer
|
|
Worldwide
|
Renal Diseases
|
Anteris Bio
|
Worldwide
|
|
Undisclosed
|
|
|
|
TTP-RA
RAGE antagonist |
T1D Prevention
|
|
|
vTv
|
Partnered
|
Notes:
TTP399: vTv has worldwide rights
TTP273: Huadong has rights for China and Pacific Rim Rights, excluding Japan
HPP737: Newsoara has rights for China and Pacific Rim Rights, excluding Japan
HPP593: Reneo has worldwide rights with vTv having equity interest in Reneo
Azeliragon: Cantex has worldwide rights
HPP971: Anteris Bio has worldwide rights with vTv having equity interest in Anteris
HPP3033: vTv has worldwide rights
TTP–RA: vTv has worldwide rights